Porton Fine Chemicals Ltd (300363) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.023x

Based on the latest financial reports, Porton Fine Chemicals Ltd (300363) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥126.55 Million ≈ $18.52 Million USD) by net assets (CN¥5.49 Billion ≈ $803.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Porton Fine Chemicals Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Porton Fine Chemicals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300363 total debt and obligations for a breakdown of total debt and financial obligations.

Porton Fine Chemicals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Porton Fine Chemicals Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Emlak Konut Gayrimenkul Yatirim Ortakligi AS
IS:EKGYO
-0.270x
Zhejiang Merit Interactive Network Technology Co Ltd Class A
SHE:300766
-0.009x
City Holding Company
NASDAQ:CHCO
0.042x
Stolt-Nielsen Limited
OL:SNI
0.060x
Shenzhen Gongjin Electn
SHG:603118
-0.028x
BillerudKorsnas AB
ST:BILL
0.015x
Wisdom Marine Lines Co Ltd
TW:2637
0.055x
West China Cement Limited
F:WFG1
0.039x

Annual Cash Flow Conversion Efficiency for Porton Fine Chemicals Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of Porton Fine Chemicals Ltd from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Porton Fine Chemicals Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥5.41 Billion
≈ $791.83 Million
CN¥405.53 Million
≈ $59.34 Million
0.075x -27.33%
2023-12-31 CN¥6.10 Billion
≈ $892.61 Million
CN¥629.06 Million
≈ $92.05 Million
0.103x -73.97%
2022-12-31 CN¥6.47 Billion
≈ $947.10 Million
CN¥2.56 Billion
≈ $375.26 Million
0.396x +245.42%
2021-12-31 CN¥4.19 Billion
≈ $612.56 Million
CN¥480.17 Million
≈ $70.26 Million
0.115x -22.83%
2020-12-31 CN¥3.39 Billion
≈ $496.54 Million
CN¥504.37 Million
≈ $73.81 Million
0.149x +29.63%
2019-12-31 CN¥3.06 Billion
≈ $448.41 Million
CN¥351.37 Million
≈ $51.42 Million
0.115x +70.75%
2018-12-31 CN¥2.88 Billion
≈ $421.91 Million
CN¥193.62 Million
≈ $28.33 Million
0.067x -66.38%
2017-12-31 CN¥1.45 Billion
≈ $212.07 Million
CN¥289.46 Million
≈ $42.36 Million
0.200x -4.09%
2016-12-31 CN¥1.37 Billion
≈ $200.49 Million
CN¥285.33 Million
≈ $41.75 Million
0.208x +118.72%
2015-12-31 CN¥1.18 Billion
≈ $172.60 Million
CN¥112.31 Million
≈ $16.43 Million
0.095x -31.71%
2014-12-31 CN¥874.42 Million
≈ $127.96 Million
CN¥121.92 Million
≈ $17.84 Million
0.139x -47.62%
2013-12-31 CN¥428.43 Million
≈ $62.69 Million
CN¥114.05 Million
≈ $16.69 Million
0.266x -23.60%
2012-12-31 CN¥327.76 Million
≈ $47.96 Million
CN¥114.21 Million
≈ $16.71 Million
0.348x +31.02%
2011-12-31 CN¥246.01 Million
≈ $36.00 Million
CN¥65.43 Million
≈ $9.57 Million
0.266x +21.40%
2010-12-31 CN¥163.21 Million
≈ $23.88 Million
CN¥35.75 Million
≈ $5.23 Million
0.219x -44.12%
2009-12-31 CN¥81.60 Million
≈ $11.94 Million
CN¥31.99 Million
≈ $4.68 Million
0.392x --

About Porton Fine Chemicals Ltd

SHE:300363 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.69 Billion
CN¥11.53 Billion CNY
Market Cap Rank
#6897 Global
#1595 in China
Share Price
CN¥21.21
Change (1 day)
-0.33%
52-Week Range
CN¥14.79 - CN¥29.41
All Time High
CN¥97.10
About

Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more